Merck's $3.9 Billion Splash Into the Hepatitis C Market

Here's what you need to know about Merck's $3.8 billion buy-out of Idenix Pharmaceuticals.

Jun 9, 2014 at 4:35PM

On the heels of uncorking a $14 billion asset sale of its consumer care business to Bayer, Merck (NYSE:MRK) is inking a deal to acquire Idenix Pharmaceuticals (NASDAQ:IDIX).

The $3.9 billion acquisition barely dents Merck's balance sheet, which sports cash and long-term investments of more than $35 billion (including the windfall from Bayer), but it offers insight into how Merck may spend its cash hoard. So let's take a closer look.

MRK Chart

MRK data by YCharts

What Merck gets
Merck wasn't shy about paying up for Idenix. The company paid a jaw-dropping $24.50 per share in cash, or 3.4 times Idenix's Friday closing price of just above $7, to capture Idenix's portfolio of potential hepatitis C treatments.

Interest in hepatitis C drugs has soared over the past few years following Gilead's (NASDAQ:GILD) $11 billion purchase of Pharmasset in 2011. That deal gave Gilead the hepatitis C drug Sovaldi, a next generation therapy that not only cut treatment periods in half to as little as 12 weeks but eliminates the use of side-effect laden interferon in some patients.

During its first full quarter on the market, Sovaldi sales rocketed north of $2 billion in Q1, but it isn't just Sovaldi's success that has likely caught Merck's attention. Despite showing inferior efficacy in trials to Sovaldi, Olysio has carved out a valuable niche as a combination therapy alongside Sovaldi in patients resistant or unable to take interferon. That niche allowed Johnson & Johnson to sell $350 million worth of Olysio in the first quarter. 

In a bid to capture a share of this market, Merck is already advancing its own hepatitis C drugs through trials and the Idenix acquisition significantly bolsters Merck's position; giving it a much larger and potentially more robust set of treatment options that it can roll-out in the coming decade.

That's important given that Merck's current hepatitis C drugs are lagging behind competing therapies from drugmakers AbbVie, which is developing a three drug hepatitis C cocktail, and Bristol-Myers, which has a promising hepatitis C drug in daclatasvir. Both AbbVie and Bristol-Myers expect decisions from the FDA soon.

Acquiring Idenix also nets Merck Idenix's intellectual property. That could give Merck a backdoor way of profiting from the hepatitis C market given that Idenix has already filed suit against Gilead alleging that Sovaldi violates its patents.

Fool-worthy final thoughts
Idenix promising drugs include Samatasvir, an NS5A inhibitor that is currently in Phase 2 trials as part of a combination therapy with Johnson's Olysio, and IDX21437, a nucleotide protein inhibitor that helps prevent the virus from replicating by targeting the NS5B protein (the same protein Gilead's Sovaldi targets).

That suggests that Merck could leverage these two drugs in multiple ways, including as part of combination therapies alongside Sovaldi, or as a Sovaldi alternative. Given the size of the check Merck wrote, the company seems to believe either of those opportunities could have multibillion blockbuster potential.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. 

The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information